Showing results (1-10 of 238) with videos related to
Sort By:
Pageof 24
The Oncologist|February 1, 2011
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancerJosé BaselgaThe Oncologist|August 31, 2002
Why the epidermal growth factor receptor? The rationale for cancer therapyJosé BaselgaJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitorsEmiliano Calvo, José BaselgaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
The epidermal growth factor receptor pathway: a model for targeted therapyMaurizio Scaltriti, José BaselgaNature Clinical Practice. Oncology|July 9, 2008
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2Aleix Prat, José BaselgaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Pharmacology in the Era of Targeted Therapies: The Case of PI3K InhibitorsEneda Toska, José BaselgaCurrent Oncology Reports|June 5, 2002
Targeting epidermal growth factor receptor in lung cancerJosé Baselga, Joan AlbanellClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Neoadjuvant therapy as a platform for drug development and approval in breast cancerAditya Bardia, José BaselgaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?Serena Di Cosimo, José BaselgaPageof 24